SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System

Smith + Nephew SNN recently announced the launch of its new TRIGEN MAX Tibia Nailing System, an advanced solution designed to treat both stable and unstable fractures of the tibia, including those involving the shaft. Notably, it is the only system currently offering trauma surgeons side-specific (right and left) nails that enable anatomic screw trajectories. This feature aims to optimize fragment fixation while minimizing soft tissue irritation, aided by the use of headless and low-profile screw options.

The TRIGEN MAX Tibia Nailing System is the latest addition to Smith + Nephew’s widely adopted TRIGEN platform and indicates a continued focus on surgeon-informed innovation in orthopedic trauma care. Its versatile design addresses a broad range of fracture patterns and surgical preferences, helping to improve intraoperative workflow and patient outcomes.

Likely Trend of SNN Stock Following the News

Shares of the company closed flat at $29.90 yesterday following the announcement. In the year-to-date period, SNN’s shares have gained 21.6% compared with the industry’s 6.6% growth. The S&P 500 increased 2.9% in the same time frame.

The launch of the new nailing system positions SNN to strengthen its foothold in the high-volume orthopedic trauma market by addressing key surgical demands for precision, efficiency and patient-centric design. With its unique offering of side-specific nails and advanced fixation features, the system is likely to drive increased adoption among trauma surgeons, especially in regions prioritizing minimally invasive and anatomically optimized procedures. Over time, this innovation could expand SNN’s market share, enhance recurring revenues from associated instruments and implants, and reinforce its reputation as a leader in orthopedic surgical technologies.

Meanwhile, SNN currently has a market capitalization of $13.07 billion. The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $6.12 billion, which indicates 10.3% growth from the fiscal 2024 reported number.

More on SNN’s TRIGEN MAX Tibia Nailing System

The TRIGEN MAX Tibia Nailing System is SNN’s latest addition to its orthopedic trauma portfolio, designed to treat stable and unstable fractures of the tibia, including shaft fractures. It is the only system to offer side-specific nails with anatomic screw trajectories, enabling improved fragment fixation and minimizing soft tissue irritation through headless and low-profile screw options.

This incorporates a two-piece modular drop system to assist with the use of ancillary instruments and enhance visualization during surgery. A 12.5 mm channel reamer is included to help preserve the integrity of the entry point while protecting surrounding soft tissue. Additionally, the system features 5.0 mm Lag Screws that allow compression of the fracture in a single screw insertion step, promoting surgical efficiency.

Built upon the long-standing success of Smith + Nephew’s TRIGEN nail family, which has been used globally for more than two decades, the TRIGEN MAX Tibia Nailing System aims to set a new standard in intramedullary tibial nailing. The system is designed as a platform capable of treating a wider range of fracture types, including more complex lower extremity trauma cases. Its surgeon-centered approach focuses on optimizing procedural workflow and aligning with individual patient anatomy. The system is currently available only in the United States, following its first clinical use earlier this month.

Favorable Industry Prospects for SNN

Per a report by Zion Market Research, the global orthopedic trauma devices market size was worth around $18.5 billion in 2022 and is predicted to grow around $38.2 billion by 2030 with a CAGR of roughly 9.5% between 2023 and 2030.

This surge is caused by the increasing prevalence of road accidents and an aging population worldwide, which together are boosting demand for advanced trauma care solutions.

SNN’s Zacks Rank & Other Stocks to Consider

SNN carries a Zacks Rank #2 (Buy) at present.

Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO.

CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.

Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently carries a Zacks Rank of 2.

Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.

AngioDynamics, currently carrying a Zacks Rank #2, reported third-quarter fiscal 2025 adjusted EPS of 3 cents in contrast to the Zacks Consensus Estimate of a loss of 13 cents. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.

ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% rise. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research